These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34406006)

  • 1. Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5
    Yun Y; Zhang C; Guo S; Liang X; Lan Y; Wang M; Zhuo N; Yin J; Liu H; Gu M; Li J; Xie X; Nan F
    J Med Chem; 2021 Aug; 64(16):12181-12199. PubMed ID: 34406006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly lipophilic 3-epi-betulinic acid derivatives as potent and selective TGR5 agonists with improved cellular efficacy.
    Wang XY; Zhang SY; Li J; Liu HN; Xie X; Nan FJ
    Acta Pharmacol Sin; 2014 Nov; 35(11):1463-72. PubMed ID: 25283506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
    Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y
    Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of betulinic acid derivatives as gut-restricted TGR5 agonists: Balancing the potency and physicochemical properties.
    Zhuo N; Yun Y; Zhang C; Guo S; Yin J; Zhao T; Ge X; Gu M; Xie X; Nan F
    Bioorg Chem; 2024 Mar; 144():107132. PubMed ID: 38241768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
    Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
    Ma SY; Ning MM; Zou QA; Feng Y; Ye YL; Shen JH; Leng Y
    Acta Pharmacol Sin; 2016 Sep; 37(10):1359-1369. PubMed ID: 27264313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of key amino acid residues in the hTGR5-nomilin interaction and construction of its binding model.
    Sasaki T; Mita M; Ikari N; Kuboyama A; Hashimoto S; Kaneko T; Ishiguro M; Shimizu M; Inoue J; Sato R
    PLoS One; 2017; 12(6):e0179226. PubMed ID: 28594916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists.
    Duan H; Ning M; Chen X; Zou Q; Zhang L; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2012 Dec; 55(23):10475-89. PubMed ID: 23148522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of betulinic acid as an agonist of TGR5 receptor using a new in vitro assay.
    Lo SH; Cheng KC; Li YX; Chang CH; Cheng JT; Lee KS
    Drug Des Devel Ther; 2016; 10():2669-76. PubMed ID: 27578964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
    Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
    J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Biological Evaluation of Covalently Mucoadhesive Derivatives as Nonsystemic Intestine-Targeted TGR5 Agonists.
    Zhao S; Wang L; Huang X; Xiao Y; Li M; Huang X; Chen X; Li S; Xie J; Liu P; Wang YD; Chen WD
    J Med Chem; 2024 Oct; 67(19):17701-17712. PubMed ID: 39321318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice.
    Li Z; Huang J; Wang F; Li W; Wu X; Zhao C; Zhao J; Wei H; Wu Z; Qian M; Sun P; He L; Jin Y; Tang J; Qiu W; Siwko S; Liu M; Luo J; Xiao J
    J Bone Miner Res; 2019 Apr; 34(4):765-776. PubMed ID: 30536462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
    Lasalle M; Hoguet V; Hennuyer N; Leroux F; Piveteau C; Belloy L; Lestavel S; Vallez E; Dorchies E; Duplan I; Sevin E; Culot M; Gosselet F; Boulahjar R; Herledan A; Staels B; Deprez B; Tailleux A; Charton J
    J Med Chem; 2017 May; 60(10):4185-4211. PubMed ID: 28414465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists.
    Zou Q; Duan H; Ning M; Liu J; Feng Y; Zhang L; Zhu J; Leng Y; Shen J
    Eur J Med Chem; 2014 Jul; 82():1-15. PubMed ID: 24863981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.
    Briere DA; Ruan X; Cheng CC; Siesky AM; Fitch TE; Dominguez C; Sanfeliciano SG; Montero C; Suen CS; Xu Y; Coskun T; Michael MD
    PLoS One; 2015; 10(8):e0136873. PubMed ID: 26312995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of triamterene as an inhibitor of the TGR5 receptor: identification in cells and animals.
    Li Y; Cheng KC; Niu CS; Lo SH; Cheng JT; Niu HS
    Drug Des Devel Ther; 2017; 11():1127-1134. PubMed ID: 28435224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursolic acid activates the TGR5 receptor to enhance GLP-1 secretion in type 1-like diabetic rats.
    Lo SH; Li Y; Cheng KC; Niu CS; Cheng JT; Niu HS
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1097-1104. PubMed ID: 28756460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects.
    Chaudhari SN; Harris DA; Aliakbarian H; Luo JN; Henke MT; Subramaniam R; Vernon AH; Tavakkoli A; Sheu EG; Devlin AS
    Nat Chem Biol; 2021 Jan; 17(1):20-29. PubMed ID: 32747812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect.
    Cao H; Chen ZX; Wang K; Ning MM; Zou QA; Feng Y; Ye YL; Leng Y; Shen JH
    Sci Rep; 2016 Jun; 6():28676. PubMed ID: 27339735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.